Cargando…
Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290310/ https://www.ncbi.nlm.nih.gov/pubmed/37353830 http://dx.doi.org/10.1186/s13223-023-00805-3 |
| _version_ | 1785062467141894144 |
|---|---|
| author | Keith, Paul K. Cowan, Juthaporn Kanani, Amin Kim, Harold Lacuesta, Gina Lee, Jason K. Chen, Jie Park, Michelle Gladiator, André |
| author_facet | Keith, Paul K. Cowan, Juthaporn Kanani, Amin Kim, Harold Lacuesta, Gina Lee, Jason K. Chen, Jie Park, Michelle Gladiator, André |
| author_sort | Keith, Paul K. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10290310 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-102903102023-06-25 Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study Keith, Paul K. Cowan, Juthaporn Kanani, Amin Kim, Harold Lacuesta, Gina Lee, Jason K. Chen, Jie Park, Michelle Gladiator, André Allergy Asthma Clin Immunol Correction BioMed Central 2023-06-23 /pmc/articles/PMC10290310/ /pubmed/37353830 http://dx.doi.org/10.1186/s13223-023-00805-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Correction Keith, Paul K. Cowan, Juthaporn Kanani, Amin Kim, Harold Lacuesta, Gina Lee, Jason K. Chen, Jie Park, Michelle Gladiator, André Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study |
| title | Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study |
| title_full | Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study |
| title_fullStr | Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study |
| title_full_unstemmed | Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study |
| title_short | Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study |
| title_sort | correction: transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: canadian real‑world study |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290310/ https://www.ncbi.nlm.nih.gov/pubmed/37353830 http://dx.doi.org/10.1186/s13223-023-00805-3 |
| work_keys_str_mv | AT keithpaulk correctiontransitioningsubcutaneousimmunoglobulin20therapiesinpatientswithprimaryandsecondaryimmunodeficienciescanadianrealworldstudy AT cowanjuthaporn correctiontransitioningsubcutaneousimmunoglobulin20therapiesinpatientswithprimaryandsecondaryimmunodeficienciescanadianrealworldstudy AT kananiamin correctiontransitioningsubcutaneousimmunoglobulin20therapiesinpatientswithprimaryandsecondaryimmunodeficienciescanadianrealworldstudy AT kimharold correctiontransitioningsubcutaneousimmunoglobulin20therapiesinpatientswithprimaryandsecondaryimmunodeficienciescanadianrealworldstudy AT lacuestagina correctiontransitioningsubcutaneousimmunoglobulin20therapiesinpatientswithprimaryandsecondaryimmunodeficienciescanadianrealworldstudy AT leejasonk correctiontransitioningsubcutaneousimmunoglobulin20therapiesinpatientswithprimaryandsecondaryimmunodeficienciescanadianrealworldstudy AT chenjie correctiontransitioningsubcutaneousimmunoglobulin20therapiesinpatientswithprimaryandsecondaryimmunodeficienciescanadianrealworldstudy AT parkmichelle correctiontransitioningsubcutaneousimmunoglobulin20therapiesinpatientswithprimaryandsecondaryimmunodeficienciescanadianrealworldstudy AT gladiatorandre correctiontransitioningsubcutaneousimmunoglobulin20therapiesinpatientswithprimaryandsecondaryimmunodeficienciescanadianrealworldstudy |